2-Fluoro-5-methylpyridine

We are 2-Fluoro-5-methylpyridine CAS:2369-19-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    2-Fluoro-5-methylpyridine
CAS.NO:2369-19-9
Synonyms:2-fluoro-5-methypyridine;
2-Fluor-5-methyl-pyridin;
2-Fluoro-5-methylpyridin;
6-Fluoro-3-picoline;
2-fluoro-5-methyl pyridine;
Molecular Formula:C6H6FN
Molecular Weight:111.11700
 
Physical and Chemical Properties:
Density:1.072 g/mL at 25 °C(lit.)
Melting point:/
Boiling point: 158-159 °C(lit.)
Flash point:119 °F
Index of Refraction: 1.473
 
Specification:
Appearance:colorless liquid
Purity:≥99.0%
 
Packing:25 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry.
Application:    used to Pharmaceutical intermediate

2-Fluoro-5-methylpyridine


Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.acetato de p-nitrofenil 2- (furfurilsulfinilo) CAS:123855-55-0 Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.4,4-Difluorocyclohexanecarboxylic Acid By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.2-Chlorobenzotrifluoride CAS:88-16-4 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
2-Chloro-3-fluoro-4-iodopyridine View Details
3-Bromo-6,9-diphenyl-9H-carbazole View Details
Methyl Valeraldehyde View Details
6,7,8,9-tetrahydrodibenzofuran-4-amine manufacturer 2,6-Dichlorobenzoxazole manufacturer Abarelix manufacturer 2,5-Difluoroaniline manufacturer 4-phenylbutyric acid manufacturer